Innoviva, Inc. (INVA)

NASDAQ: INVA · Real-Time Price · USD
19.96
+0.38 (1.94%)
At close: Jul 15, 2025, 4:00 PM
20.05
+0.09 (0.45%)
After-hours: Jul 15, 2025, 4:34 PM EDT
1.94%
Market Cap 1.25B
Revenue (ttm) 369.84M
Net Income (ttm) -59.72M
Shares Out 62.78M
EPS (ttm) -0.95
PE Ratio n/a
Forward PE 10.79
Dividend n/a
Ex-Dividend Date n/a
Volume 1,469,585
Open 19.55
Previous Close 19.58
Day's Range 19.54 - 19.99
52-Week Range 16.67 - 22.00
Beta 0.37
Analysts Strong Buy
Price Target 40.33 (+102.11%)
Earnings Date Jul 30, 2025

About INVA

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic o... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 5, 2004
Employees 127
Stock Exchange NASDAQ
Ticker Symbol INVA
Full Company Profile

Financial Performance

In 2024, Innoviva's revenue was $358.71 million, an increase of 15.54% compared to the previous year's $310.46 million. Earnings were $23.39 million, a decrease of -86.98%.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for INVA stock is "Strong Buy." The 12-month stock price target is $40.33, which is an increase of 102.11% from the latest price.

Price Target
$40.33
(102.11% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

WALTHAM, Mass. & GENEVA--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partn...

4 weeks ago - Business Wire

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

WALTHAM, Mass. & GENEVA, Switzerland--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Deve...

5 weeks ago - Business Wire

Innoviva to Participate in Upcoming Investor Conferences

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

6 weeks ago - Business Wire

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced the United States commercial availability of ZEVTERA® (ceftobipro...

2 months ago - Business Wire

Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States

Allschwil, Switzerland, May 20, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and...

2 months ago - GlobeNewsWire

Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

2 months ago - Business Wire

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

Proceeds to be used to continue to advance development of Armata's phage product candidates LOS ANGELES , March 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or...

Other symbols: ARMP
4 months ago - PRNewsWire

Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

4 months ago - Business Wire

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

4 months ago - Business Wire

Innoviva: Underappreciated Strength In Hospital Therapeutics

Innoviva's strong balance sheet and stable royalty income from GlaxoSmithKline provide a solid foundation for its shift to specialty therapeutics, presenting an asymmetric risk-reward profile. The com...

5 months ago - Seeking Alpha

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

5 months ago - Business Wire

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., (“IST”) a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced it has entered into an exclusive distribution and lic...

7 months ago - Business Wire

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting...

7 months ago - GlobeNewsWire

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

8 months ago - Business Wire

Innoviva to Participate in the UBS Global Healthcare Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

8 months ago - Business Wire

Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

8 months ago - Business Wire

Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a biotechnology company focused on delivering innovative therapies in critical care and infectious diseases, announced today the...

9 months ago - Business Wire

Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

1 year ago - Business Wire

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs

Cantor Fitzgerald has initiated coverage on Innoviva, Inc. INVA, citing the company's unique business model centered around royalties and healthcare assets.

Other symbols: GSK
1 year ago - Benzinga

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

1 year ago - Business Wire

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

1 year ago - Business Wire

Innoviva to Participate in the BofA Securities Health Care Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

1 year ago - Business Wire

Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that positive results from the Phase 3 oral zoliflodacin trial wi...

1 year ago - Business Wire

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES , March 4, 2024 /PRNewswire/ -- Armata Pharmaceuti...

Other symbols: ARMP
1 year ago - PRNewsWire

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

1 year ago - Business Wire